GynecologyGynecology2079-56962079-5831Consilium Medicum28283Research ArticleKompleks iz natural'nykh volokon snizhaet ves pri izbytochnoy masse tela i ozhirenii: dvoynoe slepoe randomizirovannoe platsebo-kontroliruemoe issledovanieGrubeBarbara-ChongPi-Vin-LauKey-Tszia-OrtsekhovskiKhans-Diter-151020131559910609042020Copyright © 2013, Consilium Medicum2013[Stevens G, Mascarenhas M, Mathers C. Global health risks: progress and challenges. Bull World Health Organ 2009; 87: 646.][Finucane M.M, Stevens G.A, Cowan M.J et al. National, regional, and global trends in body - mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country - years and 9·1 million participants. Lancet 2011; 377: 557–67.][Uwaifo A.G.I, Editor C, Griffing G.T. Obesity. Medscape Reference. 2011. Available at: <http://emedicine.medscape.com/article/123702-overview>][Wellman N.S, Friedberg B. Causes and consequences of adult obesity: health, social and economic impacts in the United States. Asia Pac J ClinNutr 2002; 11 (Suppl. 8): S705–S709.][De Wit L, Luppino F, van Straten A et al. Depression and obesity: a metaanalysis of community - based studies. Psychiatry Res 2010; 178: 230–5.][Simon G.E, Ludman E.J, Linde J.A et al. Association between obesity and depression in middle - aged women. Gen Hosp Psychiatry 2008; 30: 32–9.][Simon G.E, Von Korff M, Saunders K et al. Association between obesityand psychiatric disorders in the US adult population. Arch Gen Psychiatry 2006; 63: 824–30.][Wadden T.A, Stunkard A.J. Social and psychological consequences of obesity. Ann Intern Med 1985; 103: 1062–7.][Hammond R.A, Levine R. The economic impact of obesity in the United States. Diabetes Metab Syndr Obes 2010; 3: 285–95.][Fry J, Finley W. The prevalence and costs of obesity in the EU. Proc Nutr Soc 2005; 64: 359–62.][Bray G.A, Paeratakul S, Popkin B.M. Dietary fat and obesity: a review of animal, clinical and epidemiological studies. Physiol Behav 2004; 83: 549–55.][Sjöström L, Rissanen A, Andersen T et al. Randomised placebo - controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 167–72.][Davidson M.H, Hauptman J, Di Girolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235–42.][Rössner S, Sjöström L, Noack R et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8: 49–61.][Hauptman J, Lucas C, Boldrin M.N et al. Orlistat in the long - term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 160–7.][Collazo-Clavell M.L. Safe and effective management of the obese patient. Mayo Clin Proc 1999; 74: 1255–9; quiz 1259.][Johansson K, Neovius K, De Santis S.M et al. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta - analysis. Obes Rev 2009; 10: 564–75.][US Food and Drug Administration. Safety orlistat (marketed as Alli and Xenical): early communication about an ongoing safety review, 2009; p. 180057.][Bachmann C. Ein Fasernkomplex zur Gewichts - reduktion und - kontrolle. Ars Medici thema Phytotherapie 2010: 25–7.][International Association for the Study of Obesity. Overweight and Obesity in the EU27. International Association for the Study of Obesity: London, 2008.][Trumbo P, Schlicker S, Yates A.A, Poos M. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and aminoacids. J Am Diet Assoc 2002; 102: 1621–30.][Drent M.L, van der Veen E.A. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes Relat Metab Disord 1993; 17: 241–4.][Drent M, Larsson I, William-Olsson T et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int JObes Relat Metab Disord 1995; 19: 221–6.][US Food and Drug Administration. guidance for industry developing products for weight management guidance for industry developing products for weight management. 2007.][National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), North American Association for the Study of Obesity (NAASO). The practical guide: Identification, evaluation and treatment of overweight and obesity in adults, 2000.][Phelan S, Wadden T.A, Berkowitz R.I et al. Impact of weight loss on the metabolic syndrome. Int J Obes (Lond) 2007; 31: 1442–8.][Jull A.B, Rodgers A, Walker N. Honey as a topical treatment for wounds. Cochrane Database Syst Rev 2008: CD005083.][Van Gaal L.F, Broom J.I, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose - ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 1998; 54: 125–32.][Romero-Corral A, Virend K, Sierra-Johnson J et al. Accuracy of body mass index to diagnose obesity in the US adult population. Int J Obes (Lond) 2008; 32: 959–66.][Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord 2001; 25: 1095–9.]